Trilostane

Drug #1841

Trilostane is useful in cushing's syndrome & primary hyperaldosteronism. It reversibly inhibits ß hydroxysteroid dehydrogenase/delta 5-4 isomerase in the adrenal cortex; the resulting inhibition of the synthesis of mineralocorticoids and glucocorticoids may be useful in cushing's syndrome. It has minor role in post menopausal breast cancer that has relapsed following initial estrogen antagonist therapy.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin.

Molecular Weight: 329.4 · Non-proprietary name: Trilostane.

Pharmacokinetics

None recorded.

Indications

Trilostane is primarily indicated in conditions like Cushing's syndrome, Post menopausal breast cancer (with glucocorticoid therapy), Primary hyperaldosteronism.

Trilostane is also indicated for secondary conditions like Adrenal cortical hyperfunction, Prophylaxis of macrocytic anaemias.

Contraindications

Trilostane is contraindicated in conditions like Pregnancy, Breast feeding.

Dosage

None recorded.

Drug Interactions

None recorded.

Side Effects

Trilostane is known to cause more or less tolerable side effects which are usually transient. These include Flushing, Granulocytopenia (rarely), Mouth swelling, Rashes , Tingling .

Warnings / Precautions

Breast cancer (concurrent mineralocorticoid & glucocorticoid therapy may be needed). Adrenal cortical hyperfunction (tailored to cortisol and electrolytes, concurrent corticosteroid therapy may be needed): hepatic & renal impairrment.

Available Brands

None recorded.

Drug Classification

1.18.9 — ACTH